BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

152 related articles for article (PubMed ID: 36192339)

  • 1. LOXL2 serves as a prognostic biomarker for hepatocellular carcinoma by mediating immune infiltration and vasculogenic mimicry.
    Zhao N; Chen C; Guo Y; Liu T; Che N; Zhang D; Liang X; Zhang Y; Zhao X
    Dig Liver Dis; 2023 May; 55(5):661-672. PubMed ID: 36192339
    [TBL] [Abstract][Full Text] [Related]  

  • 2. HIF-1α promoted vasculogenic mimicry formation in hepatocellular carcinoma through LOXL2 up-regulation in hypoxic tumor microenvironment.
    Wang M; Zhao X; Zhu D; Liu T; Liang X; Liu F; Zhang Y; Dong X; Sun B
    J Exp Clin Cancer Res; 2017 Apr; 36(1):60. PubMed ID: 28449718
    [TBL] [Abstract][Full Text] [Related]  

  • 3. LOXL2 promotes vasculogenic mimicry and tumour aggressiveness in hepatocellular carcinoma.
    Shao B; Zhao X; Liu T; Zhang Y; Sun R; Dong X; Liu F; Zhao N; Zhang D; Wu L; Wang Y; Wang M; Meng J; Lin X; Sun B
    J Cell Mol Med; 2019 Feb; 23(2):1363-1374. PubMed ID: 30506621
    [TBL] [Abstract][Full Text] [Related]  

  • 4. LncRNA CARMN Affects Hepatocellular Carcinoma Prognosis by Regulating the miR-192-5p/LOXL2 Axis.
    Wang X; Wu S; Yang Y; Zhao J
    Oxid Med Cell Longev; 2022; 2022():9277360. PubMed ID: 36254230
    [TBL] [Abstract][Full Text] [Related]  

  • 5. RNA-binding protein RPS7 promotes hepatocellular carcinoma progression via LOXL2-dependent activation of ITGB1/FAK/SRC signaling.
    Zhou YJ; Yang ML; He X; Gu HY; Ren JH; Cheng ST; Fu Z; Zhang ZZ; Chen J
    J Exp Clin Cancer Res; 2024 Feb; 43(1):45. PubMed ID: 38326908
    [TBL] [Abstract][Full Text] [Related]  

  • 6.
    Yang YL; Tsai MC; Chang YH; Wang CC; Chu PY; Lin HY; Huang YH
    Int J Mol Sci; 2021 Jun; 22(11):. PubMed ID: 34206143
    [TBL] [Abstract][Full Text] [Related]  

  • 7. MARCKS on Tumor-Associated Macrophages is Correlated with Immune Infiltrates and Poor Prognosis in Hepatocellular Carcinoma.
    Ren X; Ju Y; Wang C; Wei R; Sun H; Zhang Q
    Cancer Invest; 2021 Oct; 39(9):756-768. PubMed ID: 34279157
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Multiple Roles of LOXL2 in the Progression of Hepatocellular Carcinoma and Its Potential for Therapeutic Targeting.
    Radić J; Kožik B; Nikolić I; Kolarov-Bjelobrk I; Vasiljević T; Vranjković B; Despotović S
    Int J Mol Sci; 2023 Jul; 24(14):. PubMed ID: 37511503
    [TBL] [Abstract][Full Text] [Related]  

  • 9. The pathological significance of LOXL2 in pre-metastatic niche formation of HCC and its related molecular mechanism.
    Wu S; Xing X; Wang Y; Zhang X; Li M; Wang M; Wang Z; Chen J; Gao D; Zhao Y; Chen R; Ren Z; Zhang K; Cui J
    Eur J Cancer; 2021 Apr; 147():63-73. PubMed ID: 33618200
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Increased Expression of the Matrix-Modifying Enzyme Lysyl Oxidase-Like 2 in Aggressive Hepatocellular Carcinoma with Poor Prognosis.
    Choi J; Chung T; Rhee H; Kim YJ; Jeon Y; Yoo JE; Noh S; Han DH; Park YN
    Gut Liver; 2019 Jan; 13(1):83-92. PubMed ID: 29938458
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Transcriptional analysis of the expression, prognostic value and immune infiltration activities of the COMMD protein family in hepatocellular carcinoma.
    Wang X; He S; Zheng X; Huang S; Chen H; Chen H; Luo W; Guo Z; He X; Zhao Q
    BMC Cancer; 2021 Sep; 21(1):1001. PubMed ID: 34493238
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Comprehensive analysis on the expression levels and prognostic values of LOX family genes in kidney renal clear cell carcinoma.
    Lin S; Zheng L; Lu Y; Xia Q; Zhou P; Liu Z
    Cancer Med; 2020 Nov; 9(22):8624-8638. PubMed ID: 32970930
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Identification of LOXL3-associating immune infiltration landscape and prognostic value in hepatocellular carcinoma.
    Wang N; Zhou X; Tang F; Wang X; Zhu X
    Virchows Arch; 2021 Dec; 479(6):1153-1165. PubMed ID: 34448895
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Lysyl oxidase-like 2 is critical to tumor microenvironment and metastatic niche formation in hepatocellular carcinoma.
    Wong CC; Tse AP; Huang YP; Zhu YT; Chiu DK; Lai RK; Au SL; Kai AK; Lee JM; Wei LL; Tsang FH; Lo RC; Shi J; Zheng YP; Wong CM; Ng IO
    Hepatology; 2014 Nov; 60(5):1645-58. PubMed ID: 25048396
    [TBL] [Abstract][Full Text] [Related]  

  • 15. PPM1D is a potential prognostic biomarker and correlates with immune cell infiltration in hepatocellular carcinoma.
    Yu Z; Song Y; Cai M; Jiang B; Zhang Z; Wang L; Jiang Y; Zou L; Liu X; Yu N; Mao X; Peng C; Liu S
    Aging (Albany NY); 2021 Sep; 13(17):21294-21308. PubMed ID: 34470916
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Correlation of zinc finger protein 2, a prognostic biomarker, with immune infiltrates in liver cancer.
    Sun L; Lin Y; Wang G; Zhang L; Hu L; Lu Z
    Biosci Rep; 2021 Jan; 41(1):. PubMed ID: 33439969
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Vascular endothelial growth factor A is a potential prognostic biomarker and correlates with immune cell infiltration in hepatocellular carcinoma.
    Qi Y; Song Y; Cai M; Li J; Yu Z; Li Y; Huang J; Jiang Y; Peng C; Jiang B; Liu S
    J Cell Mol Med; 2023 Feb; 27(4):538-552. PubMed ID: 36729917
    [TBL] [Abstract][Full Text] [Related]  

  • 18. CD97 serves as a novel biomarker of immune cell infiltration in hepatocellular carcinoma.
    Su Q; Li L; Li X; Li W; Zhang X; Dong Y; Han L; Wang D; Ran J
    World J Surg Oncol; 2022 Dec; 20(1):382. PubMed ID: 36464675
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Identification of CDC20 as an immune infiltration-correlated prognostic biomarker in hepatocellular carcinoma.
    Xiong C; Wang Z; Wang G; Zhang C; Jin S; Jiang G; Bai D
    Invest New Drugs; 2021 Oct; 39(5):1439-1453. PubMed ID: 33942202
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Significance of Lysyl oxidase‑like 2 gene expression on the epithelial‑mesenchymal status of hepatocellular carcinoma.
    Ninomiya G; Yamada S; Hayashi M; Takeda S; Suenaga M; Takami H; Kanda M; Iwata N; Niwa Y; Tanaka C; Kobayashi D; Fujii T; Nakayama G; Sugimoto H; Koike M; Fujiwara M; Kodera Y
    Oncol Rep; 2018 Jun; 39(6):2664-2672. PubMed ID: 29620290
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 8.